SEC Comment Letter for ALBIREO PHARMA, INC. (CIK 0001322505) — Aug 23, 2022
ALBIREO PHARMA, INC. (CIK 0001322505)
Date: Aug. 23, 2022 · CIK: 0001322505 · Accession: 0000000000-22-009062
AI Filing Summary & Sentiment
File numbers found in text: 333-266893
Letter
United States securities and exchange commission logo August 23, 2022 Ronald H.W. Cooper President and Chief Executive Officer Albireo Pharma, Inc. 53 State Street, 19th Floor Boston, Massachusetts 02109 Re:Albireo Pharma, Inc. Registration Statement on Form S-3 Filed August 16, 2022 File No. 333-266893 Dear Mr. Cooper: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Alan Campbell at 202-551-4224 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: John P. Condon, Esq.
Show Raw Text
United States securities and exchange commission logo
August 23, 2022
Ronald H.W. Cooper
President and Chief Executive Officer
Albireo Pharma, Inc.
53 State Street, 19th Floor
Boston, Massachusetts 02109
Re:Albireo Pharma, Inc.
Registration Statement on Form S-3
Filed August 16, 2022
File No. 333-266893
Dear Mr. Cooper:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Alan Campbell at 202-551-4224 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc: John P. Condon, Esq.